Adding Bevacizumab to the Treatment of Patients With Non–Small-Cell Lung Cancer: Caveat Emptor-Reference-Cited by-同舟云学术

Adding Bevacizumab to the Treatment of Patients With Non–Small-Cell Lung Cancer: Caveat Emptor

Published:2015-09 Issue:5 Volume:11 Page:363-364
ISSN:1554-7477
Container-title:Journal of Oncology Practice
language:en
Short-container-title:JOP

Author:

Hermanson Terhi T.O.¹,Hrushesky William J.¹,Knopf Kevin B.¹,Bennett Charles L.¹

Affiliation:

1. Helsinki University Hospital, Helsinki, Finland; Oncology Analytics, Plantation, FL; Sutter Healthcare System, San Francisco, CA; William Jennings Bryan Dorn Veterans Administration Medical Center; South Carolina College of Pharmacy, the University of South Carolina, Columbia; and the Hollings Cancer Center, Charleston, SC

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Health Policy,Oncology(nursing),Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JOP.2015.005397

Reference5 articles.

1. Use of Bevacizumab in Community Settings: Toxicity Profile and Risk of Hospitalization in Patients With Advanced Non–Small-Cell Lung Cancer

2. Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold

3. Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review

4. Risk of Incremental Toxicities and Associated Costs of New Anticancer Drugs: A Meta-Analysis

5. Toxicity and Costs of Toxicity Associated With New Cancer Drugs: International Implications

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-angiogenetic agents against tumor types and cardiovascular risk;Hellenic Journal of Cardiology;2017-05

2. Interpretation of surrogate endpoints in the era of the 21st Century Cures Act;BMJ;2016-12-30